Korro Bio, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Korro Bio, Inc. (KRRO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $11.68 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Korro Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.68, a 20.76% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $14.74, a 36.95% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $23.38.
- Korro Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-09-30 was $2451.00, a 266.37% increase year-over-year.
- Korro Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $17.10, a 5.32% decline from fiscal 2024.
- Korro Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $18.06, a 10.05% increase from fiscal 2023.
- Korro Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $16.41.
- Korro Bio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $16667.00, a 182.68% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.68 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $11.68 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $17.10 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $14.94 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $13.03 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $14.74 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $18.06 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $18.92 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $21.95 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $23.38 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $16.41 10-K · filed 2024-03-26 | |||
| 2020-12-31 | $16667.00 10-K · filed 2021-03-29 | |||
| 2020-09-30 | $2451.00 10-Q · filed 2020-11-16 | $9964.00 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $4297.00 10-Q · filed 2020-08-12 | $7513.00 10-Q · filed 2020-08-12 | ||
| 2020-03-31 | $3216.00 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | $5896.00 10-K · filed 2021-03-29 | |||
| 2019-09-30 | $669.00 10-Q · filed 2020-11-16 | $2842.00 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $247.00 10-Q · filed 2020-08-12 | $402.00 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $154.00 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $149.00 10-K · filed 2020-03-26 | |||
| 2018-09-30 | $2.00 10-Q · filed 2019-11-18 | $3.00 10-Q · filed 2019-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |